Streetbeat News

MNMD

Mind Medicine (MindMed) Inc.

https://www.mindmed.co

Industry

Biotechnology

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Open

7.69

Mkt cap

625M

Volume

4.6M

High

9.15

P/E Ratio

-4.16

52-wk high

12.22

Low

7.65

Div yield

N/A

52-wk low

2.41

Mind Medicine has filed a U.S. patent application (No. 20240010628) for the methods of manufacture of R-MDMA. This filing could potentially strengthen the company's intellectual property portfolio and provide a competitive edge in the development of therapeutic products based on R-MDMA.

Portfolio Pulse from Charles Gross

January 11, 2024 | 3:16 pm

The DEA has clarified that psychedelic mushroom spores are federally legal prior to germination as they do not contain psilocybin or psilocin. This clarification does not change the legal status of the spores, which are illegal in some states and may still be considered drug paraphernalia depending on their marketing or use. The DEA also discussed the legal status of marijuana seeds, delta-8 THC, and synthetic cannabinoids, indicating ongoing regulatory efforts and interpretations.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 4:41 pm

The article reports on the performance of psychedelic stocks from January 1, 2024. Cybin (CYBN) saw a gain, while ATAI Life Sciences (ATAI), Mind Medicine (MNMD), Compass Pathways (CMPS), and GH Research (GHRS) experienced losses.

Portfolio Pulse from Benzinga Insights

January 01, 2024 | 9:30 pm

President Biden signed the 2024 NDAA, which includes funding for clinical trials with psychedelics for active military members. Robert F. Kennedy Jr. expressed support for psychedelics in mental health treatment. Incannex Healthcare (NASDAQ:IXHL) is set to open Australia's first dedicated psychedelic-assisted therapy clinic. Psychedelics stocks showed varied performance, with COMPASS Pathways (NASDAQ:CMPS) closing at $8.75, and AdvisorShares Psychedelics ETF (NYSE:PSIL) closing at $1.42.

Portfolio Pulse from Lara Goldstein

December 27, 2023 | 3:09 pm

Shares of Mind Medicine (MNMD) have resumed trading. The article does not provide details on why trading was halted or what events led to the resumption.

Portfolio Pulse from Benzinga Newsdesk

December 14, 2023 | 1:00 pm

Mind Medicine (MNMD) shares are set to resume trading at 8AM ET after a temporary halt.

Portfolio Pulse from Charles Gross

December 14, 2023 | 12:58 pm

Shares of Mind Medicine (MNMD) were halted in anticipation of news, which typically indicates that significant information is about to be released that could impact the stock's price.

Portfolio Pulse from Charles Gross

December 14, 2023 | 12:34 pm

The Department of Defense Health Agency is funding a trial for PTSD treatment using Seelos Therapeutics' intranasal ketamine, SLS-002. Cybin Inc. reported strong efficacy in its Phase 2 trial of psilocybin derivative CYB003 for Major Depressive Disorder. Clearmind Medicine announced results from a pre-clinical trial combining its MEAI treatment with SciSparc's PEA for various disorders. Clearmind also underwent a reverse stock split to comply with Nasdaq's minimum bid price rule. Beckley Retreats is launching a new psilocybin retreat program, and Mindbloom is introducing a ketamine therapy program. Seelos Therapeutics launched a public offering, and other companies reported financial results or updates. The AdvisorShares Psychedelics ETF and several psychedelics stocks' trading performance are also highlighted.

Portfolio Pulse from Lara Goldstein

December 05, 2023 | 3:12 pm

Shares of psychedelic companies GH Research, Compass Pathways, ATAI Life Sciences, and Mind Medicine saw significant gains in their stock prices, while Cybin experienced a slight decline. GH Research led the gainers with a 9.06% increase, followed by Compass Pathways with a 6.00% rise. ATAI Life Sciences and Mind Medicine also posted gains of 4.67% and 4.10%, respectively. On the other hand, Cybin's shares fell by 1.61%.

Portfolio Pulse from Benzinga Insights

November 23, 2023 | 9:30 pm

The article discusses various aspects of the psychedelics industry, including the potential of psychedelic treatments for PTSD in veterans, a possible $100M IPO by a psychedelics company, and Cybin Inc.'s new $64M offering. It also covers worldwide events related to psychedelics and provides a performance overview of the AdvisorShares Psychedelics ETF (PSIL) and several psychedelics stocks. Cybin Inc. announced an underwritten offering of units at $0.45, with $30M fully funded upon closing and an additional $34M upon full exercise of warrants. The article also lists the closing prices of several psychedelics stocks on November 10, with most showing a downward trend.

Portfolio Pulse from Lara Goldstein

November 13, 2023 | 1:39 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.